Erratum: Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19) (JAMA Cardiology (2020) DOI:10.1001/jamacardio.2020.1834);Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or without Concomitant Azithromycin among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

JAMA Cardiology

Volumn 5, Issue 9, 2020, Pages 1036-1041

  Mercuro, Nicholas J ^a   Yen, Christina F ^b   Shim, David J ^b   Maher, Timothy R ^a   McCoy, Christopher M ^a   Zimetbaum, Peter J ^a,b   Gold, Howard S ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; HYDROXYCHLOROQUINE; LOOP DIURETIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CORONAVIRUS DISEASE 2019; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MASSACHUSETTS; MIDDLE AGED; NAUSEA; NOSE SMEAR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QT PROLONGATION; TERTIARY CARE CENTER; THROAT CULTURE; AGED; BETACORONAVIRUS; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; LONG QT SYNDROME; PANDEMIC; RISK ASSESSMENT; VIRUS PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; AZITHROMYCIN; BETACORONAVIRUS; COHORT STUDIES; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYCHLOROQUINE; LONG QT SYNDROME; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RISK ASSESSMENT;

EID: 85084365411     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2020.2302     Document Type: Erratum

References (15)

1. US Department of Health & Human Services, Centers for Disease Control and Prevention. Coronavirus (COVID-19). Published 2020. Accessed April 10, 2020. https://www.cdc.gov/coronavirus/2019-nCoV/index.html
2. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43 (0): E019-E9. doi:10.3760/cma.j.issn.1001-0939.2020.0019 32075365
3. Wang M, Cao R, Zhang L, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269-271. doi: 10.1038/s41422-020-0282-0 32020029
4. Gautret P, Lagier JC, Parola P, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Published online March 20, 2020. doi: 10.1016/j.ijantimicag.2020.105949 32205204
5. Molina JM, Delaugerre C, Le Goff J, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. Published online March 30, 2020. doi: 10.1016/j.medmal.2020.03.006 32240719
6. World Health Organization. The cardiotoxicity of antimalarials: Malaria Policy Advisory Committee Meeting. Published March 24, 2017. Accessed April 21, 2020. https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf
7. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366 (20): 1881-1890. doi: 10.1056/NEJMoa1003833 22591294
8. Chorin E, Dai M, Shulman E, The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. Published online April 2, 2020. Accessed April 22, 2020. https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1
9. Clerkin KJ, Fried JA, Raikhelkar J, Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020. Published online March 21, 2020. doi: 10.1161/CIRCULATIONAHA.120.046941 32200663
10. Tisdale JE, Jaynes HA, Kingery JR, Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013; 6 (4): 479-487. doi: 10.1161/CIRCOUTCOMES.113.000152 23716032
11. Grayson ML, Barber BE. Chloroquine and hydroxychloroquine. In: Grayson LM, ed. Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 7th ed. CRC Press; 2017: 3030-3047.
12. Pfizer Inc. Zithromax. Published 2019. Accessed April 21, 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=650
13. Borba MGS, Val FFA, Sampaio VS,; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020; 3 (4.23): e208857. doi: 10.1001/jamanetworkopen.2020.8857 32330277
14. Bhimraj A, Morgan RL, Shumaker AH, Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. Published April 11, 2020. Accessed April 21, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
15. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus Disease 2019) treatment [published online April 10 2020]. J Am Coll Cardiol. 2020; S0735-1097(20)34918-4. doi: 10.1016/j.jacc.2020.04.016 32283123